Literature DB >> 30220961

The dosimetric effects of limited elective nodal irradiation in volumetric modulated arc therapy treatment planning for locally advanced non-small cell lung cancer.

Mark C Kenamond1, R Alfredo Siochi2, Malcolm D Mattes2.   

Abstract

OBJECTIVE: Contemporary radiotherapy guidelines for locally advanced non-small cell lung carcinoma (LA-NSCLC) recommend omitting elective nodal irradiation, despite the fact that evidence supporting this came primarily from older reports assessing comprehensive nodal coverage using 3D conformal techniques. Herein, we evaluated the dosimetric implications of the addition of limited elective nodal irradiation (LENI) to standard involved field irradiation (IFI) using volumetric modulated arc therapy (VMAT) planning.
METHOD: Target volumes and organs-at-risk (OARs) were delineated on CT simulation images of 20 patients with LA-NSCLC. Two VMAT plans (IFI and LENI) were generated for each patient. Involved sites were treated to 60 Gy in 30 fractions for both IFI and LENI plans. Adjacent uninvolved nodal regions, considered high risk based on the primary tumor site and extent of nodal involvement, were treated to 51 Gy in 30 fractions in LENI plans using a simultaneous integrated boost approach.
RESULTS: All planning objectives for PTVs and OARs were achieved for both IFI and LENI plans. LENI resulted in significantly higher esophagus Dmean (15.3 vs. 22.5 Gy, p < 0.01), spinal cord Dmax (34.9 vs. 42.4 Gy, p = 0.02) and lung Dmean (13.5 vs. 15.9 Gy, p = 0.02), V20 (23.0 vs. 27.9%, p = 0.03), and V5 (52.6 vs. 59.4%, p = 0.02). No differences were observed in heart parameters. On average, only 32.2% of the high-risk nodal volume received an incidental dose of 51 Gy when untargeted in IFI plans.
CONCLUSION: The addition of LENI to VMAT plans for LA-NSCLC is feasible, with only modestly increased doses to OARs and marginal expected increase in associated toxicity.

Entities:  

Keywords:  Intensity modulated radiotherapy; Lung cancer; Lymph node; Non-small cell lung cancer; Radiation therapy

Year:  2017        PMID: 30220961      PMCID: PMC6135255          DOI: 10.1007/s13566-017-0327-2

Source DB:  PubMed          Journal:  J Radiat Oncol        ISSN: 1948-7908


  26 in total

1.  The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data.

Authors:  Bahman Emami; Nena Mirkovic; Charles Scott; Roger Byhardt; Mary V Graham; E James Andras; Madhu John; Arnold Herskovic; Raul Urtasun; Sucha O Asbell; Carlos A Perez; James Cox
Journal:  Lung Cancer       Date:  2003-08       Impact factor: 5.705

2.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  David S Ettinger; Douglas E Wood; Dara L Aisner; Wallace Akerley; Jessica Bauman; Lucian R Chirieac; Thomas A D'Amico; Malcolm M DeCamp; Thomas J Dilling; Michael Dobelbower; Robert C Doebele; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Leah J Leisch; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

3.  Symptomatic radiation pneumonitis in elderly patients receiving thoracic irradiation.

Authors:  Jordan Kharofa; Elizabeth Gore
Journal:  Clin Lung Cancer       Date:  2013-01-04       Impact factor: 4.785

Review 4.  State of the art in surgery for early stage NSCLC-does the number of resected lymph nodes matter?

Authors:  Laura Romero Vielva; Manuel Wong Jaen; José A Maestre Alcácer; Mecedes Canela Cardona
Journal:  Transl Lung Cancer Res       Date:  2014-04

5.  Analysis of incidental radiation dose to uninvolved mediastinal/supraclavicular lymph nodes in patients with limited-stage small cell lung cancer treated without elective nodal irradiation.

Authors:  Irfan Ahmed; Marylou DeMarco; Craig W Stevens; William J Fulp; Thomas J Dilling
Journal:  Med Dosim       Date:  2011-03-11       Impact factor: 1.482

6.  Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location.

Authors:  Christophoros S Kotoulas; Christophoros N Foroulis; Konstantinos Kostikas; Marios Konstantinou; Patra Kalkandi; Maria Dimadi; Demosthenes Bouros; Achilles Lioulias
Journal:  Lung Cancer       Date:  2004-05       Impact factor: 5.705

7.  Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma.

Authors:  Jeffrey Bradley; Joseph O Deasy; Soeren Bentzen; Issam El-Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

8.  Incidental irradiation of mediastinal and hilar lymph node stations during 3D-conformal radiotherapy for non-small cell lung cancer.

Authors:  Lucyna Kepka; Krzysztof Bujko; Agnieszka Zolciak-Siwinska; Dariusz Garmol
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

9.  A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Authors:  Shuanghu Yuan; Xindong Sun; Minghuan Li; Jinming Yu; Ruimei Ren; Yonghu Yu; Jianbin Li; Xiuqing Liu; Renben Wang; Baosheng Li; Li Kong; Yong Yin
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339

10.  Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer.

Authors:  Mark E Bernard; Scott M Glaser; Beant S Gill; Sushil Beriwal; Dwight E Heron; James D Luketich; David M Friedland; Mark A Socinski; Joel S Greenberger
Journal:  Front Oncol       Date:  2017-01-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.